YTHDF2 promotes intrahepatic cholangiocarcinoma progression and desensitises cisplatin treatment by increasing CDKN1B mRNA degradation.

Chen-Song HuangYing-Qin ZhuQiong-Cong XuSiyun ChenYue HuangGuangyin ZhaoXuhao NiBo LiuWei Zhao Xiao-Yu Yin

Published in: Clinical and translational medicine (2022)

YTHDF2 exhibits tumour oncogenic and cisplatin-desensitising properties, which may offer insight into the development of novel combination therapeutic strategies for ICC.

Keyphrases

transcription factor
replacement therapy